Jin-Xue He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin-Xue He has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Shan-Shan Song
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
15 shared publicationsXu-Bin Bao
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
9 shared publications- Ze-Hong Miao
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
8 shared publications Ze-Hong Miao
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
7 shared publicationsXia-Juan Huan
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica
6 shared publicationsAo Zhang
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, College of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing, 100049, China
5 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 151
PARP inhibitor YCH1899 activates type I interferon signaling and synergizes with STING agonists in BRCA-proficient tumors
Poly(ADP-ribose) polymerase (PARP) inhibitors are highly effective in BRCA-deficient tumors, yet their therapeutic benefit in BRCA-proficient cancers remains limited. Here, we demonstrate that YCH1899, a next-generation, resistance-overcoming PARP inhibitor, elicits significantly stronger type I interferon signaling than currently approved PARP inhibitors in BRCA-proficient tumor cells. Mechanistically, YCH1899 facilitates the accumulation of cytosolic DNA, thereby robustly activating the cGAS–STING–IRF3 pathway. Consequently, YCH1899 exhibits potent inhibitory effects on the growth of various BRCA-proficient tumors in a STING-dependent manner and enhances the infiltration of CD8⁺ T cells within the tumor microenvironment. To identify tumor-intrinsic regulators of this immune response, we conducted in vivo CRISPR screens, which revealed USP20 as a prominent regulator. The genetic ablation of USP20 markedly diminished the antitumor immunity induced by YCH1899 in vivo, suggesting that USP20 may serve as a potential predictive biomarker. Furthermore, combining YCH1899 with STING agonists synergistically amplifies interferon pathway activation, driven by enhanced phosphorylation of IRF3 at Ser173, resulting in superior tumor control and profound immune cell infiltration and activation within the tumor microenvironment. Collectively, our findings establish YCH1899 as a potent PARP inhibitor capable of extending clinical benefit to BRCA-proficient cancers and provide a rationale for its clinical combination with STING agonists to elicit robust antitumor immunity, even in patients resistant to PARP inhibitors.
- 26 August 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 151
Open AccessPARP inhibitor YCH1899 activates type I interferon signaling and synergizes with STING agonists in BRCA-proficient tumors
Poly(ADP-ribose) polymerase (PARP) inhibitors are highly effective in BRCA-deficient tumors, yet their therapeutic benefit in BRCA-proficient cancers remains limited. Here, we demonstrate that YCH1899, a next-generation, resistance-overcoming PARP inhibitor, elicits significantly stronger type I interferon signaling than currently approved PARP inhibitors in BRCA-proficient tumor cells. Mechanistically, YCH1899 facilitates the accumulation of cytosolic DNA, thereby robustly activating the cGAS–STING–IRF3 pathway. Consequently, YCH1899 exhibits potent inhibitory effects on the growth of various BRCA-proficient tumors in a STING-dependent manner and enhances the infiltration of CD8⁺ T cells within the tumor microenvironment. To identify tumor-intrinsic regulators of this immune response, we conducted in vivo CRISPR screens, which revealed USP20 as a prominent regulator. The genetic ablation of USP20 markedly diminished the antitumor immunity induced by YCH1899 in vivo, suggesting that USP20 may serve as a potential predictive biomarker. Furthermore, combining YCH1899 with STING agonists synergistically amplifies interferon pathway activation, driven by enhanced phosphorylation of IRF3 at Ser173, resulting in superior tumor control and profound immune cell infiltration and activation within the tumor microenvironment. Collectively, our findings establish YCH1899 as a potent PARP inhibitor capable of extending clinical benefit to BRCA-proficient cancers and provide a rationale for its clinical combination with STING agonists to elicit robust antitumor immunity, even in patients resistant to PARP inhibitors.
- Open Access
- 29 April 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503589
UBA3 reduction sensitizes cancer cells to NAE inhibitors
The NEDD8-activating enzyme (NAE), comprising NAE1 and UBA3, is an anticancer target. The relative contribution of each of these subunits toward NAE inhibitor (NAEi) efficacy remains unclear. We demonstrated a profound interdependence of NAE1 and UBA3 expression. UBA3 reduction augmented NAEi sensitivity, whereas its overexpression led to decreased sensitivity. UBA3 deficiency enhanced RKO xenograft sensitivity to SOMCL-19-133 (NAEi), which was reversed by UBA3 restoration. Cells with naturally low UBA3 expression were highly NAEi-sensitive. The criticality of UBA3 in NAEi sensitivity is not completely unexpected given that the ability of NAEi to directly bind to UBA3 is known. TCGA data showed that rectum adenocarcinoma patients with low UBA3 mRNA had poorer prognoses, and 27.16% of tumors expressed low UBA3 mRNA. We propose that low UBA3 expression may serve as a NAEi sensitivity biomarker, particularly given that MLN4924 (NAEi) phase 3 failures may be due to a lack of patient stratification. Therefore, our key findings, on the criticality of UBA3 in NAEi sensitivity, underpin future clinical evaluations.
- 29 April 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503589
Open AccessUBA3 reduction sensitizes cancer cells to NAE inhibitors
The NEDD8-activating enzyme (NAE), comprising NAE1 and UBA3, is an anticancer target. The relative contribution of each of these subunits toward NAE inhibitor (NAEi) efficacy remains unclear. We demonstrated a profound interdependence of NAE1 and UBA3 expression. UBA3 reduction augmented NAEi sensitivity, whereas its overexpression led to decreased sensitivity. UBA3 deficiency enhanced RKO xenograft sensitivity to SOMCL-19-133 (NAEi), which was reversed by UBA3 restoration. Cells with naturally low UBA3 expression were highly NAEi-sensitive. The criticality of UBA3 in NAEi sensitivity is not completely unexpected given that the ability of NAEi to directly bind to UBA3 is known. TCGA data showed that rectum adenocarcinoma patients with low UBA3 mRNA had poorer prognoses, and 27.16% of tumors expressed low UBA3 mRNA. We propose that low UBA3 expression may serve as a NAEi sensitivity biomarker, particularly given that MLN4924 (NAEi) phase 3 failures may be due to a lack of patient stratification. Therefore, our key findings, on the criticality of UBA3 in NAEi sensitivity, underpin future clinical evaluations.
- 4 February 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 307, 118650
Design, synthesis and biological evaluation of novel pyrrolo[1,2-b]pyridazin-2(1H)-ones as selective PARP1 inhibitors for cancer therapy
- 4 February 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 307, 118650
Design, synthesis and biological evaluation of novel pyrrolo[1,2-b]pyridazin-2(1H)-ones as selective PARP1 inhibitors for cancer therapy
- 20 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118507
Design, synthesis and biological evaluation of novel PARP inhibitors against acquired drug-resistance
- 20 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118507
Design, synthesis and biological evaluation of novel PARP inhibitors against acquired drug-resistance
- 6 August 2025
- Published by Elsevier in Cellular Signalling
- Vol. 135, 112051
Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation
- 6 August 2025
- Published by Elsevier in Cellular Signalling
- Vol. 135, 112051
Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation
- 15 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177942
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors
- 15 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177942
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors
- Open Access
- 30 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011180
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation
Backgroud: The E3 ubiquitin ligase casitas B lymphoma-b (Cbl-b) is pivotal in modulating immune responses by attenuating T-cell activation and cytokine production. Inhibiting Cbl-b presents a potential therapeutic strategy in immuno-oncology by enhancing immune activity. Methods: A rapid Homogeneous Time-Resolved Fluorescence (HTRF) assay was employed to evaluate the inhibitory efficacy of NX-1607 on Cbl-b. The effects of NX-1607 on T cell activation, cytokine production, and proliferation were characterized invitro using primary T cells and Jurkat T cells . A drug combination screening was performed utilizing the CD69 marker via flow cytometry to dentify signaling pathways involved in T cell activation by NX-1607. CRISPR/Cas9 technology was used to knock out PLCG1 and MAPK3/1 in Jurkat T cells, followed by the detection of p-PLCγ1 and p-ERK1/2 though Western blotting. The antitumor efficacy of NX-1607 was assessed in a murine model of A20 B-cell lymphoma using BALB/c mice, with subsequent flow cytometry analysis conducted to examine the phenotype of tumor-infiltrating lymphocytes (TILs). Results: Our data show that NX-1607 effectively inhibits Cbl-b activity at low nanomolar levels, boosting PLCγ1 and HCSL1 phosphorylation, activating MAPK/ERK signaling, and elevating CD69 expression. Inhibiting PLCγ1 and ERK1/2 significantly reduces NX-1607’s effect on T-cell activation. Oral administration of NX-1607 notably decreases tumor growth in the A20 B-cell lymphoma model, with immunophenotyping analyses of tumor-infiltrating lymphocytes revealing increased CD3 + , CD4 + , and CD8 + T cells in treated tumors. Furthermore, our results demonstrate that treatment with NX-1607 results in increased levels of phosphorylated PLCγ1 and ERK1/2 in circulating T cells. Conclusion: Taken together, these findings imply that the inhibition of Cbl-b by NX-1607 may enhance the activation of the MAPK/ERK signaling pathway, thereby sustaining T-cell activation. This provides compelling evidence for the molecular mechanism of NX-1607, underscoring the pivotal role of Cbl-b in controlling signal strength in T-cell activation after T-cell receptor (TCR) engagement.
- 30 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011180
Open AccessCbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation
Backgroud: The E3 ubiquitin ligase casitas B lymphoma-b (Cbl-b) is pivotal in modulating immune responses by attenuating T-cell activation and cytokine production. Inhibiting Cbl-b presents a potential therapeutic strategy in immuno-oncology by enhancing immune activity. Methods: A rapid Homogeneous Time-Resolved Fluorescence (HTRF) assay was employed to evaluate the inhibitory efficacy of NX-1607 on Cbl-b. The effects of NX-1607 on T cell activation, cytokine production, and proliferation were characterized invitro using primary T cells and Jurkat T cells . A drug combination screening was performed utilizing the CD69 marker via flow cytometry to dentify signaling pathways involved in T cell activation by NX-1607. CRISPR/Cas9 technology was used to knock out PLCG1 and MAPK3/1 in Jurkat T cells, followed by the detection of p-PLCγ1 and p-ERK1/2 though Western blotting. The antitumor efficacy of NX-1607 was assessed in a murine model of A20 B-cell lymphoma using BALB/c mice, with subsequent flow cytometry analysis conducted to examine the phenotype of tumor-infiltrating lymphocytes (TILs). Results: Our data show that NX-1607 effectively inhibits Cbl-b activity at low nanomolar levels, boosting PLCγ1 and HCSL1 phosphorylation, activating MAPK/ERK signaling, and elevating CD69 expression. Inhibiting PLCγ1 and ERK1/2 significantly reduces NX-1607’s effect on T-cell activation. Oral administration of NX-1607 notably decreases tumor growth in the A20 B-cell lymphoma model, with immunophenotyping analyses of tumor-infiltrating lymphocytes revealing increased CD3 + , CD4 + , and CD8 + T cells in treated tumors. Furthermore, our results demonstrate that treatment with NX-1607 results in increased levels of phosphorylated PLCγ1 and ERK1/2 in circulating T cells. Conclusion: Taken together, these findings imply that the inhibition of Cbl-b by NX-1607 may enhance the activation of the MAPK/ERK signaling pathway, thereby sustaining T-cell activation. This provides compelling evidence for the molecular mechanism of NX-1607, underscoring the pivotal role of Cbl-b in controlling signal strength in T-cell activation after T-cell receptor (TCR) engagement.
- Open Access
- 14 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
USP7 V517F mutation as a mechanism of inhibitor resistance
Anticipating and addressing resistance is essential for maximizing the potential of an oncology target and effectively addressing clinical needs. In this study, we aimed to proactively outline the resistance mechanisms of USP7 inhibitors. We discovered a key treatment-emergent heterozygous mutation (V517F) in USP7 in the binding pocket of compounds as the primary cause of resistance to the USP7 inhibitor USP7-797. Our structural analysis, supported by AlphaFold2 predictions, indicates that the V517F mutation altered the conformation of the compound binding pocket, causing steric hindrance and reducing the affinity between USP7 and its inhibitors. Consistent with these predictions, the affinity between V517F mutant and USP7 inhibitors was found to reduce significantly. Conversely, substitutions at position V517 with smaller side chains, such as V517G, V517A, and V517I, do not significantly impact binding affinity. In contrast, replacement with the bulkier side chain V517Y leads to reduced binding affinity and diminished inhibitor efficacy. Furthermore, the engineered cell lines harboring the V517F mutation exhibited substantial resistance to USP7 inhibition. These data provide rationales for patient selection and the development of next-generation USP7 inhibitors designed to overcome treatment-emergent mutations.
- 14 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessUSP7 V517F mutation as a mechanism of inhibitor resistance
Anticipating and addressing resistance is essential for maximizing the potential of an oncology target and effectively addressing clinical needs. In this study, we aimed to proactively outline the resistance mechanisms of USP7 inhibitors. We discovered a key treatment-emergent heterozygous mutation (V517F) in USP7 in the binding pocket of compounds as the primary cause of resistance to the USP7 inhibitor USP7-797. Our structural analysis, supported by AlphaFold2 predictions, indicates that the V517F mutation altered the conformation of the compound binding pocket, causing steric hindrance and reducing the affinity between USP7 and its inhibitors. Consistent with these predictions, the affinity between V517F mutant and USP7 inhibitors was found to reduce significantly. Conversely, substitutions at position V517 with smaller side chains, such as V517G, V517A, and V517I, do not significantly impact binding affinity. In contrast, replacement with the bulkier side chain V517Y leads to reduced binding affinity and diminished inhibitor efficacy. Furthermore, the engineered cell lines harboring the V517F mutation exhibited substantial resistance to USP7 inhibition. These data provide rationales for patient selection and the development of next-generation USP7 inhibitors designed to overcome treatment-emergent mutations.
- 5 August 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 277, 116752
Discovery of pyrrolo[2,3-d]pyrimidin-4-one derivative YCH3124 as a potent USP7 inhibitor for cancer therapy
- 5 August 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 277, 116752
Discovery of pyrrolo[2,3-d]pyrimidin-4-one derivative YCH3124 as a potent USP7 inhibitor for cancer therapy
- 14 June 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 275, 116568
Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors
- 14 June 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 275, 116568
Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors